This is a past event. Registration is closed. View other The Society of Gynecologic Oncology of Canada events.
Are you an attendee? You will have received an email from noreply@spotme.com (check your junk) that provides you with access to the platform and the meeting.
Are you a presenter? You will have received a calendar invite and a direct Zoom link.
Need help quickly? Send an email to the GOC staff at enquiry@gyneoncology.ca or text 1-888-496-3662.
AGM highlights new advancements in research and practice in the field of gynecologic oncology. This engaging professional development event offers access to world-renowned speakers, plenary talks, abstract presentations, and so much more.
Upon completion of the conference, participants will be able to:
- Identify challenges related to indigenous health across Canada
- Discuss opportunities to support and improve gynecologic oncology care for indigenous communities.
- Review the exciting data related to secondary cytoreductive surgery in ovarian cancer and improve appropriate patient selection for this procedure.
- Describe the local and international surgical clinical trials landscape
- Assess recent Canadian research in gynecologic oncology.
This is a virtual meeting. Please note that all times in the agenda on this site are in PST.
Agenda
7
30AM
-
7
35AM
Welcome and Introduction
Tomer Feigenberg7
35AM
-
8
35AM
Presidential Talk- The Joyce Echaquan Inquiry: Learning and Unlearning in Indigenous Health
Marcia AndersonAt the end of this session, participants will:
1. Understand the impact of racism on Indigenous health and health care.
2. Identify the human rights basis of Joyce's Principle.
3. Critically reflect on opportunities for action to improve health care quality for Indigenous Peoples.
8
35AM
-
8
40AM
8
40AM
-
9
05AM
Oral Abstract Presentations (3 min / 3 slides) and 2 min Q&A for each abstract presentation
Sarah Mah•Cristina Mitric•Elisabeth Spenard•Brenna SwiftAt the end of this session, participants should be able to evaluate the following studies: *Oncologic and pregnancy outcomes after fertility sparing surgery for stage I, low grade endometrioid ovarian cancer - Brenna E. Swift MD, MASc. *Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer centre: a quality improvement initiative - Sarah J. Mah MD MSc FRCSC. *Quality of end-of-life care for women with gynecologic malignancies in Ontario, Canada: a 13-year population-based retrospective analysis - Sarah J. Mah MD MSc FRCSC. *Apixaban for Postoperative Thromboprophylaxis as Standard of Care for Gynecologic Oncology Patients: A Real-World Data Study - Elisabeth Spenard MD, MSc. *Cost-analysis of an enhanced recovery program after minimally invasive gynecologic oncology surgery - Cristina Mitric MD.
9
05AM
-
9
50AM
First Break
Sponsor Symposium (15 min)
9
50AM
-
9
55AM
9
55AM
-
10
00AM
10
00AM
-
10
15AM
Video abstracts (3 minutes presentation and 2 minute Q&A)
Catriona Buick•Revital LinderAt the end of this session, participants should be able to evaluate the following studies: * Laparoscopic repair of obturator nerve injury at the time of pelvic lymphadenectomy - Revital Linder MD. * Predictors of Supportive Care in Young Women Diagnosed with a Gynecological Malignancy - Catriona J Buick RN, PhD, CON(C).
10
15AM
-
10
45AM
Oral Abstract Presentations (7 min presentations and 3 min Q&A for each presentation)
Kristin Black•Maxime Côté•Rachel KimAt the end of this session, participants should be able to evaluate the following studies: * Are mismatch repair deficient endometrial cancer recurrences more salvageable than intact cohort? - Rachel Soyoun Kim MD, MHSc, FRCSC. * The effect of transversus abdominis plane block on postoperative opioid use in gynecologic oncology patients undergoing laparotomy with Enhanced Recovery After Surgery (ERAS). - Kristin A Black MD FRCSC. * Are uterine manipulators harmful in minimally invasive surgery (MIS) for endometrial cancer? A retrospective cohort study. - Maxime Côté MD.
10
45AM
-
11
45AM
11
50AM
-
12
00PM
12
00PM
-
1
15PM
Surgical Clinical Trials. Challenges and Opportunities
Andreas du Bois•Marie Plante•Mark CareyThis will be a panel of experts that will help you discover the world of surgical clinical trials from ideation to application. They will also cover constraints such as funding. The AGO perspective: Dr. Andreas Dubois. Surgical Trials in Cervix Cancer: The SHAPE of the future, Dr. Marie Plante. Surgical Gynecological Cancer Trials and the CCTG: Dr. Mark Carey.
At the end of this session, participants will be able to: 1. Describe the framework leading to clinical trial approval in Canada. 2. Review recent successful Canadian initiated surgical clinical trials. 3. Discuss ways to engage more Canadian clinicians and centres in surgical clinical trials.
1
15PM
-
2
00PM
DeskTop Trials and Secondary Cytoreduction Debate
Andreas du Bois•Susie LauThe battle is on! Two debators will take a pro vs. con position on secondary cytoreductive surgery for recurrent ovarian cancer. Pros. Dr Andreas DuBois. vs. Cons. Dr Susie Lau
At the end of this session, participants will be able to: 1. Review available current literature related to secondary cytoreductive surgery in recurrent ovarian cancer. 2. Identify potential patients and indications for this procedure. 3. Discuss the clinical relevance and impact in the Canadian setting.
2
00PM
-
2
45PM
OvCAN Symposium
Barbara Vanderhyden•Stephanie Lheureux, MD, PhD•Helen MacKay•Alicia Tone, PhDAt the end of this session, participants will be able to: 1. Summarize the vision/mission and goals of OvCan. 2. Review the trial that has applied a “one-two punch” by combining the PARP inhibitor Veliparib with a second drug, Navitoclax. The two-pronged goal of this trial: to expand the benefits of this therapy to more women; and to prolong its effects in managing recurrences of the disease. 3. Review the NEO Trial which aims to determine how early this new therapy can be introduced in an ovarian cancer patient’s journey. The trial will compare the use of the PARP inhibitor Olaparib to standard chemotherapy applied immediately before and after surgery as a way to delay disease progression and reduce recurrences.
2
45PM
-
2
55PM
2
55PM
-
3
00PM
3
05PM
-
4
05PM
Members' Meeting: Induction of the New GOC President
For GOC Members Only
Welcome and Introduction
Speakers
Tomer Feigenberg
Gynecologic Oncologist at Trillium Health PartnersDr. Feigenberg completed his residency training in ObGyn at the Hebrew University in Jerusalem, Israel. He then completed his fellowship in gynaecologic oncology at the University of Toronto in 2013. Since then, Dr. Feigenberg has been a staff physician at Trillium Health Partners.
Presidential Talk- The Joyce Echaquan Inquiry: Learning and Unlearning in Indigenous Health
At the end of this session, participants will: 1. Understand the impact of racism on Indigenous health and health care. 2. Identify the human rights basis of Joyce's Principle. 3. Critically reflect on opportunities for action to improve health care quality for Indigenous Peoples.
Speakers
Marcia Anderson
Executive Director, Indigenous Academic Affairs of Ongomiizwin Indigenous Institute of Health and HealingDr. Marcia Anderson is Cree-Anishinaabe and grew up in the North End of Winnipeg. Her family roots go to
the Norway House Cree Nation and Peguis First Nation in Manitoba. She practices both Internal Medicine and
Public Health as a Medical Officer of Health with the Indigenous Services Canada-Manitoba Region. She is
the Vice-Dean, Indigenous Health and the Executive Director of Indigenous Academic Affairs in the
Ongomiizwin Indigenous Institute of Health and Healing, Rady Faculty of Health Sciences, University of
Manitoba. She serves as the Chair of the Indigenous Health Network of the Association of Faculties of
Medicine of Canada. She is a Past President of the Indigenous Physicians Association of Canada and Past
Chair of the Pacific Region Indigenous Doctors Congress. She was recognized for her contributions to
Indigenous peoples health with a National Aboriginal Achievement Award in March 2011. In 2018 she was
named one of the 100 most powerful women in Canada by the Women’s Executive Network.
Oral Abstract Presentations (3 min / 3 slides) and 2 min Q&A for each abstract presentation
At the end of this session, participants should be able to evaluate the following studies: *Oncologic and pregnancy outcomes after fertility sparing surgery for stage I, low grade endometrioid ovarian cancer - Brenna E. Swift MD, MASc. *Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer centre: a quality improvement initiative - Sarah J. Mah MD MSc FRCSC. *Quality of end-of-life care for women with gynecologic malignancies in Ontario, Canada: a 13-year population-based retrospective analysis - Sarah J. Mah MD MSc FRCSC. *Apixaban for Postoperative Thromboprophylaxis as Standard of Care for Gynecologic Oncology Patients: A Real-World Data Study - Elisabeth Spenard MD, MSc. *Cost-analysis of an enhanced recovery program after minimally invasive gynecologic oncology surgery - Cristina Mitric MD.
Speakers
Sarah Mah
Fellow, Gynecologic Oncology at McMaster UniversitySarah Mah is a Gynecologic Oncology fellow at McMaster University and MSc in Quality Improvement and Patient Safety from the University of Toronto Institute of Health Policy, Management and Evaluation. She completed her residency at the University of British Columbia.
Cristina Mitric
Fellow, Gynecologic Oncology at UHN- Princess Margaret Cancer CentreGynecology oncology fellow at the University of Toronto
Elisabeth Spenard
Clinical fellow at University of TorontoElisabeth Spénard is a clinical fellow in Gynecologic Oncology at the University of Toronto. She completed her medical school as well as her residency program in Obstetrics & Gynecology at the Université de Montréal, from which she graduated in 2020. In parallel with her fellowship program, she completed a Master’s in Quality Improvement and Patient Safety at the Institute of Health Policy, Management and Evaluation (IHPME) of the Dalla Lana School of Public Health in Toronto. Her research interests include hereditary cancer screening and cancer prevention as well as development of quality metrics to improve gynecologic oncology medical and surgical care.
Brenna Swift
Gyn Onc Fellow at University of TorontoBrenna Swift is a second year Gynecologic Oncology Fellow at the University of Toronto. She is concurrently completing her Masters in Health Sciences Education through McMaster University. She previously completed residency in Obstetrics & Gynaecology, medical school and a MASc in Biomedical Engineering investigating immunotherapy in cancer at the University of Toronto. Her research interests include surgical education and innovation.
Video abstracts (3 minutes presentation and 2 minute Q&A)
At the end of this session, participants should be able to evaluate the following studies: * Laparoscopic repair of obturator nerve injury at the time of pelvic lymphadenectomy - Revital Linder MD. * Predictors of Supportive Care in Young Women Diagnosed with a Gynecological Malignancy - Catriona J Buick RN, PhD, CON(C).
Speakers
Catriona Buick
Assistant Professor/ Oncology Nurse Clinician Scientist at York University /Sunnybrook Health Sciences CentreCatriona (Trina) Buick joins the School of Nursing, Faculty of Health as an assistant professor. She is an oncology specialized nurse with clinical, research and leadership experience at large academic cancer centres in Toronto and the U.K. and is a current member of the Ontario Cancer Research Ethics Board. Since the completion of her PhD (University of Toronto, 2017), she has held a nurse clinician scientist role at Sunnybrook Health Sciences Centre (Odette Cancer Centre), where her research has focused on understanding supportive care and psychosocial needs of women undergoing treatment for gynecological cancers. The overall focus of Buick’s research program is to understand the impact of HPV testing and diagnosis, promoters and barriers to cervical cancer prevention, and the role of HPV testing and acceptance as a basis for future interventions. As an advocate for patient care and (health care) system improvement, she is excited about collaborative opportunities that will continue to bridge research and clinical practice.
Revital Linder
Gynaecological Oncologist at Rambam Health Care CampusDr. Linder completed her residency in ObGyn at the Rambam Health Care Campus, Israel. She then completed her fellowship in Gynaecologic Oncology at the Trillium Health Partners hospital in July 2021. Since then, Dr. Linder has been a staff physician at Rambam Health Care Campus, Israel.
Oral Abstract Presentations (7 min presentations and 3 min Q&A for each presentation)
At the end of this session, participants should be able to evaluate the following studies: * Are mismatch repair deficient endometrial cancer recurrences more salvageable than intact cohort? - Rachel Soyoun Kim MD, MHSc, FRCSC. * The effect of transversus abdominis plane block on postoperative opioid use in gynecologic oncology patients undergoing laparotomy with Enhanced Recovery After Surgery (ERAS). - Kristin A Black MD FRCSC. * Are uterine manipulators harmful in minimally invasive surgery (MIS) for endometrial cancer? A retrospective cohort study. - Maxime Côté MD.
Speakers
Kristin Black
University of AlbertaDr. Kristin Black MD FRCSC completed her residency in obstetrics and gynecology at the University of Alberta. She is a gynecologic oncology fellow at the University of Calgary, and is concurrently taking the Master of Public Health program at the University of Victoria with a focus in Indigenous Health Studies. Her research interests ERAS and perioperative quality improvement, Indigenous health, and medical cannabis use in gynecologic oncology patients.
Maxime Côté
Fellow at Université LavalDr Maxime Côté is a first-year fellow in Gynecologic Oncology at the University Laval. He completed his medical school and residency in obstetrics and gynecology at Université Laval in 2021. His research interests are minimally invasive cancer surgery and improvement of perioperative care.
Rachel Kim
Fellow, Gynecologic Oncology at University of TorontoDr Soyoun Rachel Kim is a final year fellow in Division of Gynecology Oncology at University of Toronto. Her interests include cancer genomics, bioinformatics and hereditary gynecological malignancies
Surgical Clinical Trials. Challenges and Opportunities
This will be a panel of experts that will help you discover the world of surgical clinical trials from ideation to application. They will also cover constraints such as funding. The AGO perspective: Dr. Andreas Dubois. Surgical Trials in Cervix Cancer: The SHAPE of the future, Dr. Marie Plante. Surgical Gynecological Cancer Trials and the CCTG: Dr. Mark Carey. At the end of this session, participants will be able to: 1. Describe the framework leading to clinical trial approval in Canada. 2. Review recent successful Canadian initiated surgical clinical trials. 3. Discuss ways to engage more Canadian clinicians and centres in surgical clinical trials.
Speakers
Andreas du Bois
Medical Director KEM | Evang. Kliniken Essen-Mitte gGmbH, Germany of ESGO Center of Excellence Ovarian Cancer SurgeryProfessor Andreas du Bois completed his medical degree in 1987 at the University of Freiburg, Germany. He subsequently trained in general surgery at Krankenhaus Wolfach and Gynaecology and Obstetrics at the University of Freiburg, leading to his registration as Fellow for Gynaecology and Obstetrics in 1993.
In 1993, Prof. du Bois became a Consultant in the Department of Gynaecology and Obstetrics at St. Vincentius-Kliniken, Karlsruhe. There, he was board certified and accredited for special gynecological surgery and later for gynecological oncology. 1999, he was appointed Director of the Department of Gynaecology and Gynaecologic Oncology, Horst-Schmidt-Kliniken, Wiesbaden (19992010). 2011 he became Director of the Departmenf of Gynaecology and Gynaecologic Oncology at Kliniken Essen-Mitte, and Associate Professor at Johannes Gutenberg University of Mainz, Germany.2021 he was appointed Medical Director of the Kliniken Essen Mitte, Essen Germany.
Prof. du Bois has been the Principal Investigator of several pivotal and practice-changing international clinical trials in gynaecological oncology. He founded the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group in 1993 and co-founded the European Network of Gynaecological Oncological Trial groups (ENGOT) in 2007. He has previously been a member of the German Guideline Comittee for guidelines in breast, cervical, and ovarian cancer, Chairman of the German quality assurance programme for ovarian cancer (QS-OVAR), and member of the Gynecological Cancer InterGroup (GCIG) executive board and European Society of Gynaecological Oncology (ESGO) council. Prof. du Bois has been Chairman and a member of the Scientific Committee of the Ovarian Cancer Consensus Conference of the GCIG, and served as a member of the Scientific Committee of the 1st European Society of Medical Oncology (ESMO)-ESGO Ovarian Cancer Consensus Conference 2018. Prof. du Bois is a member of the American Society of Clinical Oncology (ASCO), ESGO, International Gynecologic Cancer Society (ISGC), German Cancer Society, and AGO. He has authored more than 500 publications with more than 33,500 citations, and has a Google Scholar h index of 87.
Prof. du Bois has received multiple honours and awards in recognition for his work, including the Arthur Walpole Award (German Cancer Society, 2006), Ernst Wertheim Award (Austrian Society of Gynecologic Oncology, 2006), MD Anderson Madrid Lifetime Award (2016), Wilhelm-Warner Prize for Cancer Research (2019), German Cancer Prize (Deutsche Krebsgesellschaft, 2020) and honorary membership of the German Society for Gynecology and Obstetrics (2020); 2021 he received the ESGO Lifetime Achievement Award (European Society of Gynaecological Oncology).
Marie Plante
Professor at CHU de Quebec - L'Hotel dieu de QuebecDr. Plante obtained her medical degree from Laval University in 1985 and completed her residency in obstetrics and gynecology at McGill University in 1990. She continued with a 3-year subspecialty in gynecologic oncology at the Memorial Sloan-Kettering Cancer Center in New York in 1993. Since then, she has worked as a gynecologist-oncologist at l’Hôtel-Dieu de Québec.
Dr. Plante is a Professor in the Department of Obstetrics and Gynecology at Laval University. She is head of the oncology-gynecology department and in charge of clinical research at l’Hôtel-Dieu de Québec.
Mark Carey
Clinical Professor at Vancouver General HospitalHe completed his medical degree and Obstetrics & Gynaecology residency at the University of Western Ontario, a fellowship in Gynaecologic Oncology at the University of Toronto and McMaster University, and a research fellowship in the Department of Systems Biology at the University of Texas, MD Anderson Cancer Centre. He runs his research program through OvCaRe and has funding through private donations and his medical corporation to support his laboratory staff. He is Co-Investigator on a recent grant award from the Cancer Research Society with Dr. Cheng-Han Lee, and has done contract research for investigational drug testing. His laboratory has been supported as well by research funds from Dr. Dianne Miller and the Division of Gyn Oncology, the BC Cancer Agency, the Carraresi Foundation OvCaRe Research Grant, and VGH and UBC Hospital Foundations. Mark regularly supervises PhD and MSc candidates and is a member of the department’s Research Advisory Committee.
DeskTop Trials and Secondary Cytoreduction Debate
The battle is on! Two debators will take a pro vs. con position on secondary cytoreductive surgery for recurrent ovarian cancer. Pros. Dr Andreas DuBois. vs. Cons. Dr Susie Lau At the end of this session, participants will be able to: 1. Review available current literature related to secondary cytoreductive surgery in recurrent ovarian cancer. 2. Identify potential patients and indications for this procedure. 3. Discuss the clinical relevance and impact in the Canadian setting.
Speakers
Andreas du Bois
Medical Director KEM | Evang. Kliniken Essen-Mitte gGmbH, Germany of ESGO Center of Excellence Ovarian Cancer SurgeryProfessor Andreas du Bois completed his medical degree in 1987 at the University of Freiburg, Germany. He subsequently trained in general surgery at Krankenhaus Wolfach and Gynaecology and Obstetrics at the University of Freiburg, leading to his registration as Fellow for Gynaecology and Obstetrics in 1993.
In 1993, Prof. du Bois became a Consultant in the Department of Gynaecology and Obstetrics at St. Vincentius-Kliniken, Karlsruhe. There, he was board certified and accredited for special gynecological surgery and later for gynecological oncology. 1999, he was appointed Director of the Department of Gynaecology and Gynaecologic Oncology, Horst-Schmidt-Kliniken, Wiesbaden (19992010). 2011 he became Director of the Departmenf of Gynaecology and Gynaecologic Oncology at Kliniken Essen-Mitte, and Associate Professor at Johannes Gutenberg University of Mainz, Germany.2021 he was appointed Medical Director of the Kliniken Essen Mitte, Essen Germany.
Prof. du Bois has been the Principal Investigator of several pivotal and practice-changing international clinical trials in gynaecological oncology. He founded the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group in 1993 and co-founded the European Network of Gynaecological Oncological Trial groups (ENGOT) in 2007. He has previously been a member of the German Guideline Comittee for guidelines in breast, cervical, and ovarian cancer, Chairman of the German quality assurance programme for ovarian cancer (QS-OVAR), and member of the Gynecological Cancer InterGroup (GCIG) executive board and European Society of Gynaecological Oncology (ESGO) council. Prof. du Bois has been Chairman and a member of the Scientific Committee of the Ovarian Cancer Consensus Conference of the GCIG, and served as a member of the Scientific Committee of the 1st European Society of Medical Oncology (ESMO)-ESGO Ovarian Cancer Consensus Conference 2018. Prof. du Bois is a member of the American Society of Clinical Oncology (ASCO), ESGO, International Gynecologic Cancer Society (ISGC), German Cancer Society, and AGO. He has authored more than 500 publications with more than 33,500 citations, and has a Google Scholar h index of 87.
Prof. du Bois has received multiple honours and awards in recognition for his work, including the Arthur Walpole Award (German Cancer Society, 2006), Ernst Wertheim Award (Austrian Society of Gynecologic Oncology, 2006), MD Anderson Madrid Lifetime Award (2016), Wilhelm-Warner Prize for Cancer Research (2019), German Cancer Prize (Deutsche Krebsgesellschaft, 2020) and honorary membership of the German Society for Gynecology and Obstetrics (2020); 2021 he received the ESGO Lifetime Achievement Award (European Society of Gynaecological Oncology).
Susie Lau
Associate Professor/Gynecologic Oncologist at McGill University/SMBD Jewish General HospitalDr. Susie Lau is an Assistant Professor appointed in the departments of Oncology and Obstetrics and Gynecology at McGill University.
She completed her medical degree at McMaster University in Hamilton, Ontario. She then went on complete her residency in Obstetrics and Gynecology at McGill University in Montreal, Quebec and became Royal College Certified in Obstetrics and Gynecology. Following this, she completed a Royal College Approved Gynecologic Oncology Fellowship Program at the University of Montreal.
At the completion of her clinical training at the University of Montreal in 2003, she returned to the McGill University Health Centre as an attending gynecologic oncologist and joined the gynecologic oncology division at the Segal Cancer Centre/SMBD Jewish General Hospital in 2005. She graduated with a Masters of Science degree in Epidemiology and Biostatistics at McGill University in 2008.
She is President of the Régroupement des Gynécologues Oncologues du Québec (RGOQ). The RGOQ is a society of individuals whose goal is the improvement of gynecologic cancer care in Quebec through education, research, and advocacy. She is also the Director of the Gynecologic Oncology fellowship program at McGill since 2012. She is an active member of the Royal College Training Committee shaping the future face of training programs in her subspecialty and is also on the Royal College Subspecialty Examination Committee.
Her research interests are diverse and include new investigational treatments and clinical trials in gynecologic cancer, as well as the application of robotic-assisted minimally invasive surgery in gynecologic oncology.
OvCAN Symposium
At the end of this session, participants will be able to: 1. Summarize the vision/mission and goals of OvCan. 2. Review the trial that has applied a “one-two punch” by combining the PARP inhibitor Veliparib with a second drug, Navitoclax. The two-pronged goal of this trial: to expand the benefits of this therapy to more women; and to prolong its effects in managing recurrences of the disease. 3. Review the NEO Trial which aims to determine how early this new therapy can be introduced in an ovarian cancer patient’s journey. The trial will compare the use of the PARP inhibitor Olaparib to standard chemotherapy applied immediately before and after surgery as a way to delay disease progression and reduce recurrences.
Speakers
Barbara Vanderhyden
Corinne Boyer Chair in Ovarian Cancer Research: Distinguished University Professor, Cellular and Molecular Medicine, University of Ottawa: Senior Scientist, Cancer Therapeutics Program at Ottawa Hospital Research InstituteBarbara Vanderhyden is the inaugural Corinne Boyer Chair in Ovarian Cancer Research, a Distinguished University Professor at the University of Ottawa, and a Senior Scientist at the Ottawa Hospital Research Institute. She spends most of her time leading a cancer research program and developing networks and resources to increase ovarian cancer research across Canada. Her current research program focuses on using new technologies to understand how cells communicate with each other in tumours, developing and improving models of ovarian cancer, and using those models to design and test novel cancer therapeutics. Dr. Vanderhyden serves on the Board of Directors of Ovarian Cancer Canada, is a Fellow of the Canadian Academy of Health Sciences, and chairs the OvCAN Governing Council which oversees a national strategic research plan to advance novel treatments for ovarian cancer. In her spare time, she established two science outreach programs: Let’s Talk Science, which makes science fun for students in elementary and high schools in the Ottawa region, and Science Travels, which sends teams of graduate students to deliver science workshops with indigenous students in remote northern communities. She has received many awards for her research, outreach, and mentorship of young scientists.
Stephanie Lheureux, MD, PhD
Clinician Investigator at Princess Margaret Cancer CentreDr. Lheureux obtained her MD in Medical Oncology and PhD in translational research from France and moved to Toronto for a Clinical Research Fellowship to focus on Gynecological Cancers and Drug Development. She is Site Lead, Gynecologic Oncology and Clinician Investigator at Princess Margaret Cancer Centre (PM) and holds an Assistant Professor position in the Faculty of Medicine, at the University of Toronto. She serves as co-Chair of the NCI Cervical Task Force on Clinical Trials and have served as a member of the Steering Committee on Uterine Cancers. She is Principal Investigator of several international studies and involved in the development of early phase clinical trials with an emphasis on drug development and translational research in gynecologic malignancies.
Her academic interest is the design and development of early phase clinical trials of targeted agents in gynecologic cancers that incorporate translational endpoints and quality of life measures. This includes but is not limited to examination of chemoprevention approaches, targeted or precision therapies, immune-oncology agents, as well as leading improvements in quality of advanced cancer care. Academically, these interests have included interrogating extreme outliers of response and resistance across the disease continuum as a means of identifying predictors of therapeutic response. In particular, deep analysis of BRCA1/2 mutations in gynecologic cancers of high grade serous histology. In the last five years, she has >40 peer-reviewed publications in widely cited journals such as CA: Cancer Journal for Clinicians (IF=244), Clinical Cancer Research, JAMA Oncology, Journal of Clinical Oncology, Lancet Oncology and Gynecology Oncology. She is PI or co-PI in several large-scale peer reviewed funding opportunities from the Canadian Cancer Society Research Institute, Ontario Institute for Cancer Research and Terry Fox Research Institute that converge preclinical and clinical areas of interest and benefit from her unique expertise in each of these domains.
Helen MacKay
Head, Division of Medical Oncology & Hematology at Sunnybrook Health Sciences CentreDr. Helen MacKay is a Medical Oncologist and Professor of Medicine at the University of Toronto. She is Head of the Division of Medical Oncology and Hematology at the Odette Cancer Centre at Sunnybrook Health Sciences Centre, and Senior Scientist at the Sunnybrook Research Institute. Dr. MacKay's clinical practice and research focus is on gynecological cancers. Her research involves collaborating with translational and basic scientists in the development and validation of novel therapeutic strategies. She is the current President of the Society of Gynecologic Oncologists of Canada (GOC). She co-chairs the NCI (US), Ovarian Cancer Task Force. She also chairs the Ovarian Group and sits on the executive of the Gyne committee of the Canadian Cancer Trials Group (CCTG), and represents CCTG at the Gynecologic Cancer Intergroup. She is a past chair of both the Gynecologic Cancer Education and Scientific Committees for ASCO. With specific reference to uterine cancers, she is a member of the TRANSPORTEC group, and sits on the Corpus Committee of NRG, and was the co-chair of the NCI Endometrial Cancer Clinical Trials Planning Committee.
Alicia Tone, PhD
Scientific Advisor & OvCAN Project Manager at Ovarian Cancer CanadaDr. Alicia Tone joined the Ovarian Cancer Canada team as Scientific Advisor in May 2019, and became OvCAN Project Manager the following November. Her deep well of experience in the ovarian cancer field includes a Ph. D. in ovarian cancer biology from the University of Toronto, postdoctoral studies in ovarian cancer genomics at B.C. Cancer Agency, and more than seven years as Scientific Associate in the Division of Gynecologic Oncology at the Princess Margaret Cancer Centre.
Recordings
Presidential Talk
The Joyce Echaquan Inquiry: Learning and Unlearning in Indigenous Health by Dr. Marcia Anderson
At the end of this session, participants will:
- Understand the impact of racism on Indigenous health and health care.
- Identify the human rights basis of Joyce's Principle.
- Critically reflect on opportunities for action to improve health care quality for Indigenous Peoples.
Oral Abstract Presentations
3 min / 3 slides
At the end of this session, participants should be able to evaluate the following studies:
- Oncologic and pregnancy outcomes after fertility sparing surgery for stage I, low grade endometrioid ovarian cancer - Brenna E. Swift, MD, MASc.
- Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer centre: a quality improvement initiative - Sarah J. Mah, MD, MSc, FRCSC.
- Quality of end-of-life care for women with gynecologic malignancies in Ontario, Canada: a 13-year population-based retrospective analysis - Sarah J. Mah, MD, MSc, FRCSC.
- Apixaban for Postoperative Thromboprophylaxis as Standard of Care for Gynecologic Oncology Patients: A Real-World Data Study - Elisabeth Spénard MD, MSc.
- Cost-analysis of an enhanced recovery program after minimally invasive gynecologic oncology surgery - Cristina Mitric MD.
Video Abstracts
At the end of this session, participants should be able to evaluate the following studies:
- Laparoscopic repair of obturator nerve injury at the time of pelvic lymphadenectomy - Revital Linder, MD.
- Predictors of Supportive Care in Young Women Diagnosed with a Gynecological Malignancy - Catriona J Buick, RN, PhD, CON(C).
Oral Abstract Presentations
7-min presentations and 3-min Q&A
At the end of this session, participants should be able to evaluate the following studies:
- Are mismatch repair deficient endometrial cancer recurrences more salvageable than intact cohort? - Rachel Soyoun Kim, MD, MHSc, FRCSC.
- The effect of transversus abdominis plane block on postoperative opioid use in gynecologic oncology patients undergoing laparotomy with Enhanced Recovery After Surgery (ERAS). - Kristin A Black, MD, FRCSC.
- Are uterine manipulators harmful in minimally invasive surgery (MIS) for endometrial cancer? A retrospective cohort study. - Maxime Côté, MD.
Surgical Clinical Trials
Challenges and Opportunities
This is a panel of experts that will help you discover the world of surgical clinical trials from ideation to application. They will also cover constraints such as funding. The AGO perspective: Dr. Andreas Dubois. Surgical Trials in Cervix Cancer: The SHAPE of the future, Dr. Marie Plante. Surgical Gynecological Cancer Trials and the CCTG: Dr. Mark Carey.
At the end of this session, participants will be able to:
- Describe the framework leading to clinical trial approval in Canada.
- Review recent successful Canadian initiated surgical clinical trials.
- Discuss ways to engage more Canadian clinicians and centres in surgical clinical trials.
DeskTop Trials and Secondary Cytoreduction Debate
The battle is on!
Two debators will take a pro vs. con position on secondary cytoreductive surgery for recurrent ovarian cancer. Pros. Dr Andreas DuBois. vs. Cons. Dr Susie Lau.
At the end of this session, participants will be able to:
- Review available current literature related to secondary cytoreductive surgery in recurrent ovarian cancer.
- Identify potential patients and indications for this procedure.
- Discuss the clinical relevance and impact in the Canadian setting.
OvCAN Symposium
Dr. Barbara Vanderhyden, Dr. Stephanie Lheureux. Dr. Helen MacKay, Dr. Alicia Tone.
At the end of this session, participants will be able to:
- Summarize the vision/mission and goals of OvCan.
- Review the trial that has applied a "one-two punch" by combining the PARP inhibitor Veliparib with a second drug, Navitoclax. The two-pronged goal of this trial: to expand the benefits of this therapy to more women; and to prolong its effects in managing recurrences of the disease.
- Review the NEO Trial which aims to determine how early this new therapy can be introduced in an ovarian cancer patient's journey. The trial will compare the use of the PARP inhibitor Olaparib to standard chemotherapy applied immediately before and after surgery as a way to delay disease progression and reduce recurrences.
Abstract Book
Tickets
Other GOC Members
C$110.-
Member Price
Buy TicketThis ticket includes members in the following categories: emeritus, nurses, other healthcare professionals and resident associates
Sponsor Representative
Free
Public Price
Reserve TicketThis option is free for representatives up to the number of spots reserved for your organization as per your sponsorship level. If you are not on the final list submitted by your organization, you will be asked to attend as an "Other Non-Members." Connect with your organization's representative before registering.
Poster Presenter
C$80.-
Public Price
Buy TicketThis ticket is only open to those who have received a poster/video acceptance for their submitted abstract.
Sponsors and Partners
Diamond
AstraZeneca/Merck
AstraZeneca is a science-led biopharmaceutical company pushing the boundaries of science to deliver life-changing medicines.
The company employs roughly 900 people in Canada who work to research, develop and market innovative medicines. AstraZeneca Canada was recently designated a global Clinical Hub for oncology and immuno-oncology clinical studies. We are currently leading global oncology clinical studies in lung, head and neck cancer.
The future of treatment for many of today’s diseases lies in uncovering mechanisms that are newly emerging or are still to be discovered. We believe the best way to help patients is to focus on breakthrough science to discover these mechanisms and develop novel, targeted therapies that interact with them. Our focus is on the following core therapy areas: Cardiovascular, Renal and Metabolic diseases (CVRM); Oncology; and Respiratory & Immunology.
In 2019, AstraZeneca invested more than $145 million in Canadian health sciences research in our core therapy areas.
AstraZeneca Canada was named one of Canada’s 10 Most Admired Cultures in 2020 by Waterstone Human Capital – a national award that recognizes best-in-class Canadian organizations with a commitment to strong and vibrant corporate cultures anchored to their people and values. The company was also recognized as being one of the top employers in the Greater Toronto Area – the seventh consecutive year AstraZeneca has received a Greater Toronto Top Employer Award. https://www.astrazeneca.ca/en
At Merck Canada, we are inspired by a shared vision and mission to save and improve lives. To make a difference in the lives of people through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future. https://www.merck.ca/en/home/
GSK
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
https://ca.gsk.com/en-ca/home/Bronze
Eisai
WHO WE ARE
Fueled by our human health care mission, we’re an inspired team of innovators relentlessly pursuing ways to improve the lives of patients and their families.
WHAT IS human health care?
It's our way of life at Eisai — giving our first thought to patients and their families. Doing so drives us to create breakthrough solutions and medicines for them.
HOW WE BRING human health care TO LIFE
Breakthrough medicines are just the beginning. human health care sparks a multitude of ways in which we improve the lives of patients, their families and caregivers.
IT’S ONE THING TO TALK ABOUT PUTTING PATIENTS FIRST. IT’S QUITE ANOTHER TO DO IT FOR MORE THAN THREE DECADES.
Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. In 2011, Eisai Canada joined in pursuing this goal. We’ve been breaking through ever since, with solutions and therapies that help improve the lives of the people we serve.
PRODUCTS
How does human health care lead to breakthrough products? The key is understanding the true needs of patients. We know in our hearts how the possibility of a breakthrough can help patients and their families keep fighting. That's why we keep fighting to discover and develop solutions.
Banzel®
Dayvigo™
Lenvima®
Halaven®
Fycompa®
For more information, please visit our website at www.eisai.ca
Gold
Merck Canada
To make a difference in the lives of people through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.
https://www.merck.ca/en/home